Tag: chymotrypsinogen

August 30, 2017

Propanc Biopharma Gives Update on Upcoming Study

Propanc Biopharma provided an update on the starting stages of their First-In-Human study towards the full-scale manufacture of the investigational...
July 18, 2017

Propanc Biopharma Announces Joint Research Partnership with Jaen University

Propanc Biopharma established a four-year joint research partnership with the Jaén University in Spain to expand the company's product pipeline.
June 9, 2017

Propanc Biopharma Gives Update on PCT Patent Application

Propanc Biopharma shared a key update on its Patent Cooperation Treaty patent application within its intellectual property.
June 1, 2017

Propanc Biopharma Changes Ticker Symbol

Propanc Biopharma announced it has changed the company's ticker symbol from PPCH to PPCB.
May 19, 2017

Propanc Shares Data on Lead Product Treating Cancer

Propanc Biopharma announced new insights about how cancer stem cells can resist standard treatments, become more aggressive and spread rapidly.
May 2, 2017

Propanc Gives Update on PRP Study

Propanc Biopharma provided an update on the development of the GMP-compliant investigational medicinal product (IMP) manufacture of PRP for First-In-Human...
April 27, 2017

Propanc Wraps Toxicity Study on PRP

Propanc Biopharma completed a 28-day toxicity study showing that PRP, the company's lead product, showed no toxicological findings after administration.